Focused On-demand Library for Alpha-2,8-sialyltransferase 8B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92186

UPID:

SIA8B_HUMAN

Alternative names:

Sialyltransferase 8B; Sialyltransferase St8Sia II; Sialyltransferase X

Alternative UPACC:

Q92186; Q4VAZ0; Q92470; Q92746

Background:

Alpha-2,8-sialyltransferase 8B, also known as Sialyltransferase 8B, Sialyltransferase St8Sia II, and Sialyltransferase X, plays a crucial role in the modification of glycoproteins by transferring sialic acid through alpha-2,8-linkages. This enzymatic activity is pivotal for the expression of polysialic acid (PSA) on N-linked oligosaccharides, influencing cell-cell interactions and signaling pathways.

Therapeutic significance:

Understanding the role of Alpha-2,8-sialyltransferase 8B could open doors to potential therapeutic strategies. Its involvement in the biosynthesis of polysialic acid, a key player in cellular communication and adhesion, highlights its potential as a target in diseases where these processes are dysregulated.